FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049004338> ?p ?o ?g. }

• W2049004338 endingPage "35" @default.
• W2049004338 startingPage "28" @default.
• W2049004338 abstract "OBJECTIVES: Irritable bowel syndrome (IBS) affects 10–15% of the population, and treatment options are limited. Rifaximin is a minimally absorbed antibiotic that has shown efficacy in IBS patients. The objective of our study was to perform a meta-analysis and systematic review of available randomized, placebo controlled trials evaluating the efficacy and tolerability of rifaximin in patients with IBS. METHODS: We performed a systematic literature search of multiple online electronic databases regardless of language. Inclusion criteria entailed randomized, placebo controlled trials and IBS defined by accepted symptom-based criteria. Meta-analysis was conducted to evaluate the summary odds ratios (ORs) and 95% confidence intervals (CIs) of combined studies for the primary and secondary outcomes using a random-effects model based on the DerSimonian and Laird method to reflect both within- and between study variability. We assessed heterogeneity usingχ2 test and the inconsistency index statistic (I2). Significant heterogeneity was defined asI2 ≥25%. Meta-regression was performed using generalized linear mixed-effects model and study as random effects to estimate the summary OR adjusting for covariate differences across studies and treatment group. Publication bias was assessed by funnel plot analysis. RESULTS: Systematic review identified 13,700 citations. Eighteen were deemed to be potentially relevant, of which five articles met eligibility. Meta-analysis found rifaximin to be more efficacious than placebo for global IBS symptom improvement (OR=1.57; 95% CI=1.22, 2.01; therapeutic gain=9.8%; number needed to treat (NNT)=10.2), with mild heterogeneity (P=0.25,I2=26%). For the key secondary outcome of bloating, raw data were available for four studies. Rifaximin was significantly more likely to improve bloating than placebo (OR=1.55; 95% CI=1.23–1.96; therapeutic gain=9.9%; NNT=10.1), with no significant heterogeneity (P=0.27,I2=23%). We found that studies with older patients and more females demonstrated higher response rates, which was consistent regardless of treatment group. In addition, studies with higher cumulative dose tended to report a higher response rate. Of the covariates evaluated, we found age to be most predictive of response, with a correlation coefficient of 0.97 between aggregate response rate and mean age in the placebo groups. Although studies with higher cumulative dose tended to show increased response rates, this was also seen consistently in both the treated and placebo groups. Adverse effects were similar among patients receiving rifaximin or placebo in all studies. The most common adverse events (AEs) (≤10%) with rifaximin were headache, upper respiratory infection, nausea, nasopharygitis, diarrhea, and abdominal pain. Serious AEs were rare (<1%) and similar with rifaximin and placebo. CONCLUSIONS: Rifaximin proved more effective than placebo for global symptoms and bloating in IBS patients. The modest therapeutic gain was similar to that yielded by other currently available therapies for IBS. AEs were similar between rifaximin and placebo." @default.
• W2049004338 created "2016-06-24" @default.
• W2049004338 creator A5027136649 @default.
• W2049004338 creator A5031267224 @default.
• W2049004338 creator A5072644098 @default.
• W2049004338 creator A5075026914 @default.
• W2049004338 date "2012-01-01" @default.
• W2049004338 modified "2023-10-11" @default.
• W2049004338 title "The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis" @default.
• W2049004338 cites W1606920119 @default.
• W2049004338 cites W1972248676 @default.
• W2049004338 cites W1976491162 @default.
• W2049004338 cites W1977777269 @default.
• W2049004338 cites W1980588138 @default.
• W2049004338 cites W1980848546 @default.
• W2049004338 cites W1988399731 @default.
• W2049004338 cites W1999734650 @default.
• W2049004338 cites W2003111718 @default.
• W2049004338 cites W2009348105 @default.
• W2049004338 cites W2016124588 @default.
• W2049004338 cites W2024601462 @default.
• W2049004338 cites W2027701604 @default.
• W2049004338 cites W2028889492 @default.
• W2049004338 cites W2043462457 @default.
• W2049004338 cites W2047118920 @default.
• W2049004338 cites W2047233471 @default.
• W2049004338 cites W2049952239 @default.
• W2049004338 cites W2050866386 @default.
• W2049004338 cites W2051267760 @default.
• W2049004338 cites W2052689271 @default.
• W2049004338 cites W2058681706 @default.
• W2049004338 cites W2059521692 @default.
• W2049004338 cites W2064201279 @default.
• W2049004338 cites W2068114187 @default.
• W2049004338 cites W2070888548 @default.
• W2049004338 cites W2074514990 @default.
• W2049004338 cites W2077005896 @default.
• W2049004338 cites W2085025024 @default.
• W2049004338 cites W2087956925 @default.
• W2049004338 cites W2088812362 @default.
• W2049004338 cites W2090190545 @default.
• W2049004338 cites W2091033035 @default.
• W2049004338 cites W2094432191 @default.
• W2049004338 cites W2103771013 @default.
• W2049004338 cites W2107328434 @default.
• W2049004338 cites W2120896017 @default.
• W2049004338 cites W2124821571 @default.
• W2049004338 cites W2125423663 @default.
• W2049004338 cites W2127983504 @default.
• W2049004338 cites W2131048380 @default.
• W2049004338 cites W2131830842 @default.
• W2049004338 cites W2137048847 @default.
• W2049004338 cites W2138430214 @default.
• W2049004338 cites W2141397074 @default.
• W2049004338 cites W2146147731 @default.
• W2049004338 cites W2149216059 @default.
• W2049004338 cites W2150568622 @default.
• W2049004338 cites W2163741559 @default.
• W2049004338 cites W2169545883 @default.
• W2049004338 cites W236432269 @default.
• W2049004338 cites W346972081 @default.
• W2049004338 doi "https://doi.org/10.1038/ajg.2011.355" @default.
• W2049004338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22045120" @default.
• W2049004338 hasPublicationYear "2012" @default.
• W2049004338 type Work @default.
• W2049004338 sameAs 2049004338 @default.
• W2049004338 citedByCount "241" @default.
• W2049004338 countsByYear W20490043382012 @default.
• W2049004338 countsByYear W20490043382013 @default.
• W2049004338 countsByYear W20490043382014 @default.
• W2049004338 countsByYear W20490043382015 @default.
• W2049004338 countsByYear W20490043382016 @default.
• W2049004338 countsByYear W20490043382017 @default.
• W2049004338 countsByYear W20490043382018 @default.
• W2049004338 countsByYear W20490043382019 @default.
• W2049004338 countsByYear W20490043382020 @default.
• W2049004338 countsByYear W20490043382021 @default.
• W2049004338 countsByYear W20490043382022 @default.
• W2049004338 countsByYear W20490043382023 @default.
• W2049004338 crossrefType "journal-article" @default.
• W2049004338 hasAuthorship W2049004338A5027136649 @default.
• W2049004338 hasAuthorship W2049004338A5031267224 @default.
• W2049004338 hasAuthorship W2049004338A5072644098 @default.
• W2049004338 hasAuthorship W2049004338A5075026914 @default.
• W2049004338 hasConcept C126322002 @default.
• W2049004338 hasConcept C142724271 @default.
• W2049004338 hasConcept C156957248 @default.
• W2049004338 hasConcept C168563851 @default.
• W2049004338 hasConcept C187960798 @default.
• W2049004338 hasConcept C194661718 @default.
• W2049004338 hasConcept C197934379 @default.
• W2049004338 hasConcept C204787440 @default.
• W2049004338 hasConcept C27081682 @default.
• W2049004338 hasConcept C2778271842 @default.
• W2049004338 hasConcept C2778375690 @default.
• W2049004338 hasConcept C2778889925 @default.
• W2049004338 hasConcept C2780439572 @default.
• W2049004338 hasConcept C2908647359 @default.

• next